Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
1999-02-24
2001-02-27
Shah, Mukund J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S258100, C544S215000, C544S263000, C544S281000
Reexamination Certificate
active
06194410
ABSTRACT:
FIELD OF THE INVENTION
The present invention is relates to pyrazolopyrimidines and pyrazolo-triazines of the general formula
wherein
R
1
is phenyl, optionally substituted by one or more lower alkyl, halogen or lower alkoxy; tolyl; pyridyl; naphthyl; or thiophenyl;
R
2
is hydrogen; lower alkyl; lower thioalkyl; or hydroxy-lower-alkoxy;
R
3
is amino; lower alkylamino; di-lower-alkyl-amino; piperazinyl, optionally substituted by one or more lower alkyl, benzyl, phenyl or hydroxy-lower-alkyl; morpholinyl; imidazolyl; (CH
3
)
2
N(CH
2
)
n
NH—; (CH
3
)
2
N(CH
2
)
n
)O— or morpholinyl—(CH
2
)
n
O— in which n signifies 2 or 3;
R
4
is hydrogen; lower alkyl; or hydroxy-lower-alkyl;
R
5
is hydrogen; halogen; lower alkyl; C
3
-C
6
-cycloalkyl; lower alkyl-lower-alkoxy; hydroxy-lower-alkyl-lower-alkoxy; (CH
3
)
2
N(CH
2
)
n
NH—; piperazinyl, optionally substituted by lower alkyl; methyl-piperazinyl, optionally substituted by lower alkyl; morpholinyl; methyl-morpholinyl; di-lower-alkylamino; or di-lower-alkylamino-lower-alkyl; or
R
4
and R
5
together represent —(CH
2
)
m
— or —CH
2
—S—CH
2
— wherein m is 3 or 4, and their pharmaceutically acceptable salts.
BACKGROUND OF THE INVENTION
These compounds surprisingly evidence a selective affinity to 5HT-6 receptors. They are accordingly suitable for use in the treatment and prevention of central nervous disorders such as, for example, psychoses, schizophrenia, manic depressions (Bryan L. Roth et al., J. Pharmacol. Exp. Ther., 268, pages 1403-1410 (1994)), depressions (David R. Sibley et al., Mol. Pharmacol., 43, pages 320-327 (1993)), neurological disorders (Anne Bourson et al., J. Pharmacol. Exp. Ther., 274, pages 173-180 (1995); R. P. Ward et al., Neuroscience, 64, pages 1105-1110 (1995)), memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease and Huntington's chorea (Andrew J. Sleight et al., Neurotransmissons, 11, pages 1-5 (1995)).
Preferred is the treatment of Alzheimer's disease.
Objects of the present invention are the novel compounds of formula I-A and I-B and their pharmaceutically useable salts, the use of these compounds as therapeutically active substances, the manufacture of these compounds, medicaments containing one or more of these compounds, optionally in the form of one of their pharmaceutically useable salts, as well as the production of such medicaments.
Preferred compounds of general formula I-A are those in which R
3
represents amino, such as, for example
3-benzenesulphonyl-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine,
3-(4-isopropyl-benzenesulphonyl) -5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]-pyrimidin-7-ylamine,
5-methyl-2-methylsulphanyl-3-(naphthalene-2-sulphonyl) -pyrazolo[1,5-a]pyrimidin-7-ylamine,
3-(4-fluoro-benzenesulphonyl)-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine,
3-benzenesulphonyl-5-cyclopropyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine,
3-benzenesulphonyl-2-methylsulphanyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-ylamine,
3-benzenesulphonyl-5-isopropyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine,
5-methyl-2-methylsulphanyl-3-(toluene-2-sulphonyl)-pyrazolo[1,5-a]pyrimidin-7-ylamine,
5-methyl-2-methylsulphanyl-3-(toluene-3-sulphonyl)-pyrazolo[1,5-a]pyrimidin-7-ylamine,
3-benzenesulphonyl-5-methoxymethyl-2-methylsulphanyl-pyrazolo[1,5 -a]pyrimidin-6-ylamine,
3-benzenesulphonyl-N5,N5-dimethyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-5,7-diamine,
3-benzenesulphonyl-N5-(2-dimethylamino-ethyl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-5,7-diamine,
3-benzenesulphonyl-5-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine and
3-benzenesulphonyl-5-dimethylamineomethyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ylamine.
Additionally preferred, compounds of formula I-A are those in which R
3
represents piperazinyl, such as, for example,
3-benzenesulphonyl-5-methyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine,
3-(4-tert-butyl-benzenesulphonyl)-5-methyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine,
3-benzenesulphonyl-5,6-dimethyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo-[1,5-a]pyrimidine,
3-benzenesulphonyl-2-methylsulphanyl-7-piperazin-1-yl-5-propyl-pyrazolo[1,5-a]pyrimidine,
3-benzenesulphonyl-5-cyclopropyl-2-methylsulphanyl-7-piperazin-1-yl-pyrazolo[1,5-a]pyrimidine,
3-benzenesulphonyl-2-methylsulphanyl-8piperazin-1-yl-6,7-dihydro-5H-cyclo-penta[d]pyrazolo[1,5-a]pyrimidine,
3-benzenesulphonyl-2-methylsulphanyl-8-piperazin-1-yl-5H,7H-pyrazolo[1,5-a]thieno[3,4-d]pyrimidine,
5-methyl-2-methylsulphanyl-7-piperazin-1-yl-3-(thiophen-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine,
3-benzenesulphonyl-2-ethyl-8-piperazin-1-yl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine and
5-methyl-2-methylsulphanyl-7-piperazin-1-yl-3-(toluol-2-sulphonyl)-pyrazolo[1,5-a]pyrimidine.
Furthermore, there are preferred compounds of formula I-A and I-B in which R
3
represents methylpiperazinyl, such as, for example,
3-benzenesulphonyl-5-cyclopropyl-2-methylsulphanyl-7-(4-methylpiperazin-1-yl) -pyrazolo[1,5-a]pyrimidine,
3-benzenesulphonyl-8-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine,
3-benzenesulphonyl-8-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-5H,7H-pyrazolo[1,5-a]thieno[3,4-d]pyrimidine,
3-benzenesulphonyl-5-isopropyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine and
2-[3-benzenesulphonyl-7-(4-methyl-piperazin-1-yl)-2-methylsulphanyl-pyrazolo-[1,5-a]pyrimidine-5-yloxy]-ethanol.
8-Benzenesulphonyl-7-methylsulphanyl-pyrazolo[1,5-a][1,3,5]triazin-4-ylamine and 8-benzenesulphonyl-2-methyl-4-(4-methylpiperazin-1-yl)-7-methylsulphanyl-pyrazolo[1,5-a][1,3,5]triazine are other preferred triazines of general formula I-B.
The term “lower alkyl” as used in the present description denotes residues from 1 to 7, preferably from 1 to 4, carbon atoms, such as, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl and t-butyl.
The term “lower alkoxy” denotes a lower alkyl residue in the sense of the foregoing definition bonded via an oxygen atom, such as, for example, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy and t-butoxy.
The term “lower alkylamino” denotes a lower alkyl residue in the sense of the foregoing definition bonded via an NH group, such as, for example, methylamino and ethylamino.
The term “di-lower-alkylamino” represents identical or different lower alkyl residues in the sense of the foregoing definition bonded via a nitrogen atom, such as, for example, dimethylamino, diethylamino or methyl-ethyl-amino.
The term “halogen” includes fluorine, chlorine, bromine and iodine.
The term “lower thioalkyl” denotes a lower alkyl residue in the sense of the foregoing bonded via a sulphur atom.
The preparation of the novel compounds can be effected in a manner known to one skilled in the art. Specifically, compounds of formula I-A may be synthesized as is described in Examples 1-123. Compounds of formula I-B maybe synthesized as is described in Examples 124-129. Furthermore, Schemes 1-3 provide a general overview with respect to the alternatives available for the preparation of these novel compounds, the starting compounds of formula III in Scheme 1 being prepared in a manner analogous to described methods.
The compounds of formula I-A and I-B also include those compounds in which hydrogen can be replaced by tritium.
DETAILED DESCRIPTION OF THE INVENTION
The compounds of formula I-A and I-B can be prepared by reacting a compound of the formula
or a compound of the formula
with a compound of the formula
HR
3
wherein R
1
—R
5
are as described above. Optionally
Bos Michael
Riemer Claus
Stadler Heinz
Ebel Eileen M.
Hoffman-La Roche Inc.
Johnston George W.
Rocha-Tramaloni Patricia S.
Shah Mukund J.
LandOfFree
Pyrazolopyrimidine and pyrazolines and process for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazolopyrimidine and pyrazolines and process for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolopyrimidine and pyrazolines and process for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2613297